Treatment
Temozolomide clinical trials
We’re tracking 143 recruiting studies that include Temozolomide, each written for real people, not researchers, below.
Recruiting studies
- NCT05083754RecruitingPhase 1
New glioblastoma trial testing immune drug plus radiation
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
Baltimore, MarylandAges 18–100 - NCT04919382RecruitingPhase 2
Temozolomide plus atezolizumab for advanced small cell lung cancer
This trial studies temozolomide plus atezolizumab in people with metastatic or recurring small cell lung cancer that has already come back or progressed after standard platinum chemotherapy plus immunotherapy. It may help by trying a new combination after prior treatment has stopped working.
Chicago, IllinoisAges 18 years+ - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT04765514RecruitingPhase 2
Chemo with radiation versus chemo alone for older brain tumor patients
This trial compares two standard treatments for newly diagnosed glioblastoma (a serious brain cancer) in older and frail patients: chemo plus radiation versus chemo alone. It may help determine which approach works best and is safest for people in your age and health group.
Calgary, AlbertaAges 65 years+ - NCT04689347RecruitingPhase 1/Phase 2
New chemotherapy and targeted drug for a specific colon cancer type
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
Milan, MilanAges 18–75 - NCT03213002RecruitingPhase 1/Phase 2
CAPTEM pills after brain radiation for newly diagnosed glioblastoma
This trial studies whether taking two chemotherapy pills (capecitabine and temozolomide) after the initial 6-week radiation-and-chemo phase can help people with newly diagnosed glioblastoma. It aims to test safety and early effectiveness right before the usual maintenance temozolomide phase.
New York, New YorkAges 18–74 - NCT06072586RecruitingEarly Phase 1
Study of BDTX-1535 for brain tumors with EGFR changes
This trial tests a new drug, BDTX-1535, for people with a type of brain tumor called high-grade glioma that has a specific change in the EGFR gene. The study looks at how the drug works in the body and how safe it is for both newly diagnosed and recurrent tumors.
Chandler, ArizonaAges 18 years+ - NCT05789043RecruitingPhase 3
Test of immunotherapy plus pills and chemotherapy for advanced melanoma
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
BeijingAges 18 years+ - NCT06220552RecruitingPhase 2
Low-dose radiation plus immunotherapy for recurrent glioblastoma
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
Zhuhai, GuangdongAges 18 years+ - NCT06283927Recruiting
Surgery vs. medical care for recurrent glioblastoma
This trial compares surgery to the best non-surgical treatment for people whose glioblastoma has come back. The goal is to see which approach helps people live longer with a better quality of life.
San Francisco, CaliforniaAges 18–90 - NCT06297512RecruitingPhase 2
Testing chemotherapy after radiation for young patients with glioblastoma
This trial tests whether a type of chemotherapy called anthracycline can help young patients with glioblastoma when given after radiation therapy. It aims to see if this treatment improves outcomes for patients aged 3 to 30.
FlorenceAges 3–30 - NCT06327451RecruitingPhase 2
Atorvastatin plus temozolomide for EGFR-positive glioblastoma
This trial tests whether adding the cholesterol drug atorvastatin to the standard chemotherapy temozolomide improves outcomes for people with a specific type of glioblastoma (brain cancer) that is positive for the EGFR protein. It aims to find a more effective treatment for this aggressive tumor.
TianjinAges 18–60 - NCT06330337RecruitingPhase 3
Electroacupuncture plus paclitaxel for recurrent high-grade glioma
This trial tests whether adding electroacupuncture (a type of acupuncture with mild electric pulses) to the chemotherapy drug paclitaxel can help people with recurrent high-grade glioma. The goal is to see if the combination works better than paclitaxel alone.
ZhejiangAges 18–70 - NCT05664464RecruitingPhase 1/Phase 2
Glutamate drugs for newly diagnosed brain tumor treatment
This Phase 1/2 study tests whether “glutamate inhibitor” medications can be safely added for newly diagnosed glioblastoma, and how they affect treatment outcomes. It’s designed for adults who will also receive the standard chemo‑radiation plan with temozolomide.
Zurich, Canton of ZurichAges 18 years+ - NCT04625907RecruitingPhase 1/Phase 2
Study testing treatment options for children and adults with RMS
This study tests different treatment approaches for rhabdomyosarcoma (RMS) in children and adults, including newly diagnosed high-risk cases, people needing radiotherapy, and people whose RMS has returned. It’s designed to find safer dosing and more effective therapy while checking whether participants can proceed based on health and timing requirements.
BrisbaneAges Any age - NCT06008106RecruitingPhase 3
Tunlametinib pill vs chemo for advanced NRAS melanoma
This trial tests a new pill called Tunlametinib (a MEK inhibitor) compared to standard chemotherapy for people with advanced melanoma that has a specific NRAS gene change and no longer responds to immunotherapy. It aims to see if the new pill works better or is safer than chemo.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06514313RecruitingPhase 2
Study of a drug combo for children with returning soft tissue sarcoma
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
Guangzhou, GuangdongAges 2–21 - NCT07670026RecruitingPhase 2
Stronger treatment after surgery for high-risk glioblastoma
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
Hangzhou, ZhejiangAges 18 years+ - NCT06739395RecruitingPhase 2
Precision cancer trial for patients out of standard options
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07549321RecruitingPhase 2/Phase 3
Hu14 Immunotherapy for High-Risk Neuroblastoma in Children
This study tests a new antibody-based immunotherapy called hu14 for children and young adults with high-risk neuroblastoma (an aggressive childhood cancer that has spread). The treatment is designed to help the immune system fight cancer cells.
San Francisco, CaliforniaAges 1.5 years–18 years - NCT06760117RecruitingPhase 1
Gene-guided chemo for kids with relapsed solid tumors
This trial tests a new combination of chemotherapy drugs (irinotecan, temozolomide, and vincristine) for children whose solid tumors have come back or not responded to standard treatment. It aims to see if a specific gene test can help doctors choose the right dose of irinotecan to reduce side effects.
Guangzhou, GuangdongAges Up to 18 years - NCT07492680RecruitingPhase 2
Study of BMS-986504 for solid tumors with MTAP deletion
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
San Francisco, CaliforniaAges 18 years+ - NCT07476794RecruitingPhase 2
Daily temozolomide for elderly patients with newly diagnosed brain cancer
This trial tests a daily chemo drug (temozolomide) in patients aged 65 or older with a specific type of aggressive brain cancer that has a certain genetic marker. It aims to see if this daily schedule works well after initial radiation and chemo.
Toronto, OntarioAges 65 years+ - NCT07452458RecruitingPhase 3
Pulsed vs standard radiation for newly diagnosed glioblastoma
This trial tests a new way of giving radiation therapy (pulsed) compared to standard radiation for people with a specific type of glioblastoma (IDH wildtype, MGMT unmethylated). The goal is to see if the pulsed approach helps with thinking and memory while still treating the tumor.
Irvine, CaliforniaAges 18 years+
Common questions
- Are there clinical trials studying Temozolomide?
- Yes. Clin2 currently lists 143 recruiting studies that include Temozolomide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Temozolomide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Temozolomide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Temozolomide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.